LncRNAs exhibit high specificity to target tissues and cells, which may help to reduce toxic effects associated with cancer therapy. LncRNAs can be successfully targeted with antisense oligonucleotides (ASOs) to represent a new class of targets for tumor therapy.
UCSF researchers have developed a radiation modifier screen using CRISPRi to identify specific lncRNAs that sensitize glioma cells to radiotherapy. The invention also comprises methods for generating a human brain organoid model of malignant glioma.
· Potential to:
o increase efficacy of radiation therapy, a key adjunctive cancer therapy
o selectively inhibit glioma cell growth via lncRNA knockdown without toxicity to normal brain cells
· Method of treating malignant glioma and/or inhibiting growth / proliferation of glioma cells
· Enhancement of radiation therapy efficacy
· Method of screening therapeutic agents / radiotherapy sensitizers
To commercialize the technology
Proof of concept
Available under CDA